Kwangho Kim

This inventor holds 19 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Small Molecule Inhibitors. Top assignees: Vanderbilt University, The UAB Research Foundation (The University of Alabama at Birmingham), The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kwangho Kim. Retrieved from https://idiyas.com/inventor/kwangho-kim-jh0ppw70

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 2)

% Patents Active = 94.7

CIPO Patents = 3

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 9.8

ph-index = 4

Forward Citations = 30(Granted Patents)

Company Filing History:

19 out of 1,226

Vanderbilt University

patents

6 out of 642

The UAB Research Foundation (The University of Alabama at Birmingham)

patents

6 out of 3,705

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

4. 6 out of 2,665

University of Pennsylvania

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

Areas of Expertise:

Lactate Dehydrogenase

Mcl-1 Inhibitors

Chrysophaentin

Indole Compounds

Insect Sensing

Hypoxia Imaging

Small Molecules

Pyrazole

Compositions

Inhibition

Probes

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12398115 - Chrysophaentin analogs and use thereof (2025-08-26),

2. 12365653 - Small molecule inhibitors of lactate dehydrogenase and methods of use thereof (2025-07-22),

3. 12195472 - Substituted indole Mcl-1 inhibitors (2025-01-14),

4. 12144816 - Substituted indole Mcl-1 inhibitors (2024-11-19),

5. 11897845 - Small molecule inhibitors of lactate dehydrogenase and methods of use thereof (2024-02-13),

6. 11596639 - Substituted indole Mcl-1 inhibitors (2023-03-07),

7. 11484032 - Compositions for inhibition of insect sensing (2022-11-01),

8. 11247971 - Small molecule inhibitors of lactate dehydrogenase and methods of use thereof (2022-02-15),

9. 11208415 - Substituted indole Mcl-1 inhibitors (2021-12-28),

10. 10961200 - Small molecule inhibitors of lactate dehydrogenase and methods of use thereof (2021-03-30),

11. 10954228 - 1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof (2021-03-23),

12. 10954193 - Substituted indole Mcl-1 inhibitors (2021-03-23),

13. 10813355 - Compositions for inhibition of insect sensing (2020-10-27),

14. 10533010 - Substituted indole Mcl-1 inhibitors (2020-01-14),

15. 10351532 - Small molecule inhibitors of lactate dehydrogenase and methods of use thereof (2019-07-16),

Title: Kwangho Kim: Pioneering Innovations in Cancer Treatment

Introduction

Kwangho Kim, located in Nashville, TN, is a prominent inventor who has made significant contributions to the field of medical research and pharmaceutical development. With a remarkable portfolio of 18 patents, he is recognized for his innovative solutions aimed at addressing critical health issues, particularly in oncology.

Latest Patents

Among Kwangho Kim's latest patents, two noteworthy inventions stand out. The first patent is related to "Small molecule inhibitors of lactate dehydrogenase and methods of use thereof." This invention presents a compound with the potential to treat cancer effectively. The patent details methods of utilizing this compound to inhibit lactate dehydrogenase A (LDHA) and lactate dehydrogenase B (LDHB) activity in cells, highlighting its application in treating patients with cancer cells that exhibit resistance to conventional anti-cancer agents.

The second notable patent is for "Substituted indole Mcl-1 inhibitors." This invention aims to inhibit the activity of the anti-apoptotic protein Myeloid cell leukemia-1 (Mcl-1), which is known to be over-expressed in various cancers. The patent outlines pharmaceutical compositions and methods for using these compounds to treat diseases characterized by Mcl-1 dysregulation, further emphasizing their potential in cancer therapy.

Career Highlights

Kwangho Kim has built an impressive career through his work at esteemed institutions. He has been affiliated with Vanderbilt University and the UAB Research Foundation, where he has contributed his expertise in research focused on cancer treatment. His innovative work has not only led to multiple patents but also advanced scientific understanding in critical therapeutic areas.

Collaborations

Throughout his career, Kwangho Kim has collaborated with notable colleagues, such as Plamen P. Christov and Gary Allen Sulikowski. These collaborations have facilitated the exchange of ideas and knowledge, enhancing their collective ability to innovate and develop effective solutions in the realm of medical research.

Conclusion

Kwangho Kim stands out as a leading innovator in cancer treatment, with an extensive portfolio of patents that highlight his commitment to advancing healthcare. His groundbreaking work, particularly in the development of small molecule inhibitors, reflects his dedication to finding new ways to combat cancer and improve patient outcomes. As he continues his research, the potential impact of his innovations on the medical field remains significant.

Profile summary based on public USPTO records.